WuXi Biologics receives Investment Bank Analyst Rating Update
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Chinese authorities have been cracking down on public companies—a topic we covered (here, here, and here). There has been increased regulatory oversight in diverse sectors,...
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
|Moving Averages||Sell||Strong Sell||Strong Sell||Strong Sell||Sell|
|Technical Indicators||Strong Sell||Strong Sell||Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|